title: [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
abstract: Glucocorticoids were widely used for the treatment of various disorders. Therefore, the management of glucocorticoid-induced osteoporosis (GIOP) is referred to doctors who take care of underlying diseases. Since glucocorticoid-induced bone loss is most rapid during the initial 3-6 months, primary prevention of bone loss is especially important.The Japanese Society of Bone and Mineral Metabolism have devised a guideline for the management of GCOP and bisphosphonates play a central role for the primary and secondary prevention of GIOP. Human PTH (1-34) , teriparatide is possible another beneficial drug in addition to bisphosphonates.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Shinji
authors.initials: S
authors.lastname: Sato
mesh_terms: D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000378:metabolism / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011322:Primary Prevention; D019379:Teriparatide / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D019379:Teriparatide